Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788956 | 1.00 | ALDH1A1 (0.37) | ALDH1A1PKMHSD11B1OPRM1OPRL1 | |
| SCHEMBL788957 | 1.00 | ALDH1A1 (0.37) | ALDH1A1PKMHSD11B1OPRM1OPRL1 | |
| SCHEMBL789013 | 1.00 | ALDH1A1 (0.37) | ALDH1A1PKMHSD11B1OPRM1OPRL1 | |
| SCHEMBL789124 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PKM | |
| SCHEMBL789272 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PKM | |
| SCHEMBL9567813 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PKM | |
| SCHEMBL10752789 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PKM | |
| SCHEMBL789556 | 0.94 | ALDH1A1 (0.33) | ALDH1A1PKM | |
| SCHEMBL789484 | 0.94 | ALDH1A1 (0.33) | ALDH1A1PKM | |
| SCHEMBL16938253 | 0.94 | ALDH1A1 (0.33) | ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | ALDH1A1 1739/4885PKM 1398/4885HSD11B1 160/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | ALDH1A1 2027/4885PKM 2807/4885HSD11B1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.